Polydeoxyribonucleotide for the improvement of a hypertrophic retracting scar-An interesting case report

Post-surgery disabling scars are frequent after surgical interventions.

We evaluated a new strategy for scars management.

A woman with a postsurgery disabling scar, consequent to an accident that needed surgical intervention, had serious difficulties to walk and perform normal daily activities. A few months after the intervention, she was treated with a combined therapy consisting of polydeoxyribonucleotide (PDRN) vials 5.625 mg/3 mL (administered subcutaneously as a biostimulant treatment through the scars and throughout the whole atrophic area), associated with nucleotide administered topically and as a food supplement. The patient was treated with an additional topical nighttime treatment cream based on nucleotides, hyaluronic acid, Allium cepa extract, and vitamin E, plus a daily treatment with a cream containing nucleotides, and a nutraceutical systemic treatment with 25 mg/cps of nucleotides and 5 mg/cps of Q10-coenzyme (1 cps/d).

This reasonably cheap treatment was effective and safe for this disabling scar at the right foot. One year after starting treatment, the patient confirmed her complete satisfaction. This is the first case report describing an unexpectedly successful outcome while using this combination therapy on a woman with a postsurgery disabling scar.